Rothman R B, Baumann M H, Dersch C M, Appel J, Houghten R A
Clinical Psychopharmacology Section, DIR, NIDA, NIH, Baltimore, Maryland, USA.
Synapse. 1999 Sep 1;33(3):239-46. doi: 10.1002/(SICI)1098-2396(19990901)33:3<239::AID-SYN8>3.0.CO;2-R.
The acute reinforcing effects of cocaine are thought by some to result from cocaine binding to the dopamine (DA) transporter, which inhibits DA uptake and increases synaptic DA levels in the mesolimbic system. Other data suggest that neurotransmitters other than DA contribute to cocaine reinforcement and addiction. These considerations illustrate the need to have additional research tools with which to test the "DA hypothesis." One strategy is to identify drugs which bind to the DA transporter (DAT ligands) but which do not inhibit DA uptake as effectively as cocaine. The purpose of the present study was to identify members of a novel structural class of DAT ligands and to characterize their interactions at the DA transporter. A positional scanning hexapeptide D-amino acid library was screened for inhibition of [(125)I]RTI-55 binding to rat caudate DA transporters. Based on the results, 12 peptides were synthesized. All 12 peptides inhibited [(125)I]RTI-55 binding to DA transporters with IC(50) values, which ranged from 1.8 microM to 12 microM. The two most potent peptides (TPI-669-1 and TPI-669-4) were prepared in larger quantities and were characterized further for activity at the DAT and 5-HT transporter. Both peptides inhibited DA and 5-HT uptake and transporter binding with IC(50)/K(i) values in the low micromolar range. In vivo microdialysis studies demonstrated that both peptides increase extracellular DA and 5-HT in the nucleus accumbens of rats. These data demonstrate that peptides can function as inhibitors of biogenic amine transport. Future work will focus on developing more potent and selective peptides. Published 1999 Wiley-Liss, Inc.
一些人认为,可卡因的急性强化作用是由于可卡因与多巴胺(DA)转运体结合,从而抑制DA摄取并增加中脑边缘系统中的突触DA水平。其他数据表明,除DA之外的神经递质也参与了可卡因的强化作用和成瘾过程。这些考虑因素表明需要有更多的研究工具来检验“DA假说”。一种策略是鉴定与DA转运体结合(DAT配体)但不像可卡因那样有效抑制DA摄取的药物。本研究的目的是鉴定一类新型结构的DAT配体成员,并表征它们在DA转运体上的相互作用。对一个位置扫描六肽D-氨基酸文库进行筛选,以检测其对[(125)I]RTI-55与大鼠尾状核DA转运体结合的抑制作用。根据结果,合成了12种肽。所有12种肽均抑制[(125)I]RTI-55与DA转运体的结合,IC(50)值范围为1.8 microM至12 microM。制备了两种活性最强的肽(TPI-669-1和TPI-